CTOs on the Move

Institut National de Sante Publique du Quebec

www.inspq.qc.ca

 
Our goal is to advance knowledge and propose crosssectoral strategies and endeavours that will improve the health and well-being of Québecers. The Institut national de santé publique du Québec (INSPQ) was created in 1998 following the adoption of its act of incorporation (RSQ, chapter I-13.1.1). Its experts come from fields as distinct as applied science, health sciences, social sciences, and humanities and work with the health and social services network to develop and pool public health knowledge and skills.
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.inspq.qc.ca
  • 945, av Wolfe
    Quebec City, QC CAN G1V 5B3
  • Phone: 418.650.5115

Executives

Name Title Contact Details

Similar Companies

Mount Evans Hospice

Mount Evans Hospice is a Evergreen, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rappahannock Area Community Services Board

At RACSB, we are committed to helping community members lead the best lives possible, whether they need a little lift or a lifetime of support.

C C Young

C C Young is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Dallas, TX. To find more information about C C Young, please visit www.ccyoung.org

Contexo Media

Contexo Media is a Sandy, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.